Corcept Therapeutics CORT Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's total liabilities & equity?
- Corcept Therapeutics (CORT) reported total liabilities & equity of $814.88M in Q1 2026.
- How has Corcept Therapeutics's total liabilities & equity changed year-over-year?
- Corcept Therapeutics's total liabilities & equity decreased by 3.7% year-over-year, from $846.46M to $814.88M.
- What is the long-term trend for Corcept Therapeutics's total liabilities & equity?
- Over 5 years (2020 to 2025), Corcept Therapeutics's total liabilities & equity has grown at a 7.9% compound annual growth rate (CAGR), from $571.73M to $836.65M.
- What does total liabilities & equity mean?
- The sum of all company debts and shareholder equity, which equals total assets.
- How do you interpret total liabilities & equity?
- Changes in this figure reflect the overall growth or contraction of the company's balance sheet size.
- How does total liabilities & equity compare across companies?
- A fundamental accounting identity used to assess the scale of a company's operations.